Evidence-Based Integrative Medicine

, Volume 2, Issue 4, pp 207–228 | Cite as

Clinical Drug Interactions with Medicinal Herbs

Review Article


The problem of herb-drug interactions is being increasingly recognised. However, except for hypericum (Hypericum perforatum L.; St John’s wort), data on drug interactions with other herbs are still inconclusive, although research has started to fill in the gaps, and knowledge is being gained about this important safety issue. This review summarises clinical data on interactions between drugs and herbal medicines, which were compiled using the following databases: MEDLINE via PubMed, Web of Science® (from their inception until March 2005) and the Cochrane Library (until 2005, issue 1). Clinical data on herb-drug interactions, observed in case reports, case series or clinical trials, were included. Results are described for the following herbs: Devil’s claw (Harpagophytum procumbens D.C.), echinacea, evening primrose (Oenothera biennis L.), garlic (Allium sativum L.), ginkgo (Ginkgo biloba L.), goldenseal (Hydrastis canadensis L.), hawthorn, kava (Piper methysticum Forst.), milk thistle (Silybum marianum [L.] Gaertn.), peppermint, saw palmetto (Serenoa repens [Bartel] Small) and valerian. Information on herb-drug interactions is discussed through use of in vivo and experimental data, and conclusions are drawn when possible.


  1. 1.
    Pirmohamed M, James S, Meakin S, et al. Adverse drag reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–9PubMedCrossRefGoogle Scholar
  2. 2.
    Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drag reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200–5PubMedCrossRefGoogle Scholar
  3. 3.
    Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine 2001; 8: 401–9PubMedCrossRefGoogle Scholar
  4. 4.
    Johne A, Brockmöller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforation). Clin Pharmacol Ther 1999; 66: 338–45PubMedCrossRefGoogle Scholar
  5. 5.
    Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet 2000; 355: 547–8PubMedCrossRefGoogle Scholar
  6. 6.
    Johne A, Schmider J, Brockmöller J, et al. Lowered plasma levels of amitriptyline and its metabolites upon co-medication with an extract from St. John’s wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22: 46–54PubMedCrossRefGoogle Scholar
  7. 7.
    Wentworth JM, Agostini M, Love J, et al. St John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166: R11–6PubMedCrossRefGoogle Scholar
  8. 8.
    Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the Saint John’s wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330–40PubMedCrossRefGoogle Scholar
  9. 9.
    Henderson L, Yue QY, Bergquist C, et al. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349–56PubMedCrossRefGoogle Scholar
  10. 10.
    Johne A, Roots I. Adverse drug effects and interactions: what is the current thinking about the use of St. John’s wort? [in German]. Pharm Unserer Zeit 2003; 32: 242–6PubMedCrossRefGoogle Scholar
  11. 11.
    Mannel M. Drug interactions with St John’s wort: mechanisms and clinical implications. Drug Saf 2004; 27: 773–97PubMedCrossRefGoogle Scholar
  12. 12.
    Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158: 2200–11PubMedCrossRefGoogle Scholar
  13. 13.
    Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134–8PubMedCrossRefGoogle Scholar
  14. 14.
    Ernst E. Interactions between synthetic and herbal medicinal products. Part 2: a systemic review of the direct evidence. Perfusion 2000; 13: 60–70Google Scholar
  15. 15.
    Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286: 208–16PubMedCrossRefGoogle Scholar
  16. 16.
    Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163–75PubMedCrossRefGoogle Scholar
  17. 17.
    Bhattaram VA, Graefe U, Kohlert C, et al. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 2002; 9: 1–33PubMedCrossRefGoogle Scholar
  18. 18.
    Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002; 32: 451–78PubMedCrossRefGoogle Scholar
  19. 19.
    Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35: 35–98PubMedCrossRefGoogle Scholar
  20. 20.
    Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587–95PubMedCrossRefGoogle Scholar
  21. 21.
    Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Saf 1997; 17: 342–56PubMedCrossRefGoogle Scholar
  22. 22.
    Vaddadi KS. The use of gamma-linolenic acid and linoleic acid to differentiate between temporal lobe epilepsy and schizophrenia. Prostaglandins Med 1981; 6: 375–9PubMedCrossRefGoogle Scholar
  23. 23.
    Holman CP, Bell AFJ. A trial of evening primrose oil in the treatment of chronic schizophrenia. J Orthomolecular Psychiatry 1983; 12: 302–4Google Scholar
  24. 24.
    Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet 1979; I: 607CrossRefGoogle Scholar
  25. 25.
    Sunter WH. Warfarin and garlic [letter]. Pharm J 1991; 246: 722Google Scholar
  26. 26.
    Pathak A, Leger P, Bagheri H, et al. Garlic interaction with fluindione: a case report. Therapie 2003; 58: 380–1PubMedCrossRefGoogle Scholar
  27. 27.
    Laroche M, Choudri S, Gallicano K, et al. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic [abstract]. Can J Infect Dis 1998; 9Suppl. A: 471PGoogle Scholar
  28. 28.
    Haase G, Riethling AK, Drewelow B. Serious ADR associated with Ginkgo biloba [abstract]. Eur J Clin Pharmacol 2002; 58: S95Google Scholar
  29. 29.
    Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46: 1775–6PubMedCrossRefGoogle Scholar
  30. 30.
    Hoffman T. Ginko, Vioxx and excessive bleeding: possible drug-herb interactions: case report. Hawaii Med J 2001; 60: 290PubMedGoogle Scholar
  31. 31.
    Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997; 336: 1108PubMedCrossRefGoogle Scholar
  32. 32.
    Hauser D, Gayowski T, Singh N. Bleeding complications precipitated by unrecognized Gingko biloba use after liver transplantation. Transpl Int 2002; 15: 377–9PubMedCrossRefGoogle Scholar
  33. 33.
    Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis 2003; 167: 367PubMedCrossRefGoogle Scholar
  34. 34.
    Matthews Jr MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998; 50: 1933–4PubMedCrossRefGoogle Scholar
  35. 35.
    Galluzzi S, Zanetti O, Binetti G, et al. Coma in a patient with Alzheimer’s disease taking low dose trazodone and gingko biloba. J Neurol Neurosurg Psychiatry 2000; 68: 679–80PubMedCrossRefGoogle Scholar
  36. 36.
    Granger AS. Ginkgo biloba precipitating epileptic seizures. Age Ageing 2001; 30: 523–5PubMedCrossRefGoogle Scholar
  37. 37.
    Schelosky L, Raffauf C, Jendroska K, et al. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58: 639–40PubMedCrossRefGoogle Scholar
  38. 38.
    Ballesteros S, Adan S, Ramon MF, et al. Severe adverse effect associated with kava kava [abstract]. J Toxicol Clin Toxicol 2001; 39: 312Google Scholar
  39. 39.
    Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125: 940–1PubMedGoogle Scholar
  40. 40.
    Yue QY, Jansson K. Herbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. J Am Geriatr Soc 2001; 49: 838PubMedCrossRefGoogle Scholar
  41. 41.
    Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. Psychiatr Serv 1999; 50: 969–70PubMedGoogle Scholar
  42. 42.
    Yager J, Siegfreid SL, DiMatteo TL. Use of alternative remedies by psychiatric patients: illustrative vignettes and a discussion of the issues. Am J Psychiatry 1999; 156: 1432–8PubMedGoogle Scholar
  43. 43.
    Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75: 89–100PubMedCrossRefGoogle Scholar
  44. 44.
    Gurley BJ, Gardner SF, Hubbard MA, et al. Assessment of botanical supplementation on human cytochrome P450 phenotype: citrus aurantium, echinacea, milk thistle, saw palmetto. Clin Pharmacol Ther 2004; 76: 428–40PubMedCrossRefGoogle Scholar
  45. 45.
    Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003; 55: 199–202PubMedCrossRefGoogle Scholar
  46. 46.
    Piscitelli SC, Burstein AH, Weiden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234–8PubMedCrossRefGoogle Scholar
  47. 47.
    Jacek H, Rentsch KM, Steinert HC, et al. No effect of garlic extract on saquinavir kinetics and hepatic CYP3A4 function measured by the erythromycin breath test [abstract]. Pharmacol Ther 2004; 75: P80Google Scholar
  48. 48.
    Markowitz JS, Devane CL, Chavin KD, et al. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003; 74: 170–7PubMedCrossRefGoogle Scholar
  49. 49.
    Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276–87PubMedCrossRefGoogle Scholar
  50. 50.
    Loizou GD, Cocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum Exp Toxicol 2001; 20: 321–7PubMedCrossRefGoogle Scholar
  51. 51.
    Gwilt PR, Lear CL, Tempero MA, et al. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev 1994; 3: 155–60PubMedGoogle Scholar
  52. 52.
    Tebonin® Fachinformation. Karlsruhe, Germany: Dr Willmar Schwabe GmbH & Co., 2004. (Data on file)Google Scholar
  53. 53.
    Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomised, double blind, placebo-crossover trial. Thromb Haemost 2002; 87: 1075–6PubMedGoogle Scholar
  54. 54.
    Yasui-Furukori N, Furukori H, Kaneda A, et al. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 2004; 44: 538–42PubMedCrossRefGoogle Scholar
  55. 55.
    Duche JC, Barre J, Guinot P, et al. Effect of Ginkgo biloba extract on microsomal enzyme induction. Int J Clin Pharmacol Res 1989; 9: 165–8PubMedGoogle Scholar
  56. 56.
    Smith M, Lin KM, Zheng YP. An open trial of nifedipine-herb interactions: nifedipine with St. John’s wort, ginseng or Ginkgo biloba. Clin Pharmacol Ther 2001; 69: P86Google Scholar
  57. 57.
    Sun H, Zuo Z, Yin OQ, et al. A “high-throughput” cocktail method for screening the effect of herbal product on liver isozyme activities: experience with Ginkgo biloba. Clin Pharmacol Ther 2002; 71: P100CrossRefGoogle Scholar
  58. 58.
    Mauro VF, Mauro LS, Kleshinski JF, et al. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 2003; 10: 247–51PubMedCrossRefGoogle Scholar
  59. 59.
    Markowitz JS, Donovan JL, Devane CL, et al. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 2003; 23: 576–81PubMedCrossRefGoogle Scholar
  60. 60.
    Yin OQ, Tomlinson B, Waye MM, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841–50PubMedCrossRefGoogle Scholar
  61. 61.
    Yoshioka M, Ohnishi N, Koishi T, et al. Studies on interactions between functional foods or dietary supplements and medicines: IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004; 27: 2006–9PubMedCrossRefGoogle Scholar
  62. 62.
    Uchida S, Yamada H, Li XD, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam [abstract]. Clin Exp Pharmacol Physiol 2004; 31: A219–20CrossRefGoogle Scholar
  63. 63.
    Greenblatt DJ, von Moltke LL, Perloff ES, et al. Effect of ginkgo on CYP2C9: in vitro and in vivo studies. Clin Pharmacol Ther 2005; 77: P48CrossRefGoogle Scholar
  64. 64.
    Sandhu RS, Prescilla RP, Simonelli TM, et al. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol 2003; 43: 1283–8PubMedCrossRefGoogle Scholar
  65. 65.
    Gurley BJ, Gardner SF, Williams DK, et al. Effect of goldenseal, black cohosh, kava kava, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4 phenotypes [abstract]. Clin Pharmacol Ther 2005; 77: P36CrossRefGoogle Scholar
  66. 66.
    Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003; 43: 637–42PubMedGoogle Scholar
  67. 67.
    Russmann S, Barguil Y, Wenk M, et al. Traditional aqueous kava extracts inhibit CYP4501A2 in humans [abstract]. Clin Pharmacol Ther 2004; 75: P83CrossRefGoogle Scholar
  68. 68.
    Herberg KW. Safety-related performance after intake of kava-extract, bromazepam and their combination [in German]. Z Allgemeinmed 1996; 72: 973–7Google Scholar
  69. 69.
    Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev 1997; 16: 147–55PubMedCrossRefGoogle Scholar
  70. 70.
    Herberg KW. Effect of kava-special extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters [in German]. Blutalkohol 1993; 30: 96–105PubMedGoogle Scholar
  71. 71.
    Leber HW, Knauff S. Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittelforschung 1976; 26: 1603–5PubMedGoogle Scholar
  72. 72.
    Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002; 22: 551–6PubMedCrossRefGoogle Scholar
  73. 73.
    DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003; 23: 866–70PubMedCrossRefGoogle Scholar
  74. 74.
    Mills E, Wilson K, Clarke M, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 2005; 61(1): 1–7PubMedCrossRefGoogle Scholar
  75. 75.
    Gurley BJ, Hubbard MA, Barone G, et al. Assessment of milk thistle and black cohosh supplementation on digoxin pharmacokinetics [abstract]. Clin Pharmacol Ther 2005; 77: P49CrossRefGoogle Scholar
  76. 76.
    Rajnarayana K, Reddy MS, Vidyasagar J, et al. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 2004; 54: 109–13PubMedGoogle Scholar
  77. 77.
    Dresser GK, Wacher V, Wong S, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002; 72: 247–55PubMedCrossRefGoogle Scholar
  78. 78.
    Dresser GK, Wacher V, Ramtoola Z, et al. Peppermint oil increases the oral bioavailability of felodipine and simvastatin [abstract]. Clin Pharmacol Ther 2002; 71: P67CrossRefGoogle Scholar
  79. 79.
    Markowitz JS, Donovan JL, Devane CL, et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003; 74: 536–42PubMedCrossRefGoogle Scholar
  80. 80.
    Mayer B, Springer E. Psychoexperimental studies on the effect of a valepotriate combination as well as the combined effects of valtratum and alcohol [in German]. Arzneimittelforschung 1974; 24: 2066–70PubMedGoogle Scholar
  81. 81.
    Kohnen R, Oswald WD. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry 1988; 21: 447–8PubMedCrossRefGoogle Scholar
  82. 82.
    Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32: 1333–6PubMedCrossRefGoogle Scholar
  83. 83.
    Gagnier JJ, Chrubasik S, Manheimer E. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med 2004; 4: 13PubMedCrossRefGoogle Scholar
  84. 84.
    Wegener T. Die Teufelskralle (Harpagophytum procumbens DC.) in der Therapie rheumatischer Erkrankungen. Z Phytother 1998; 19: 284–94Google Scholar
  85. 85.
    Loew D, Mollerfeld J, Schrodter A, et al. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Clin Pharmacol Ther 2001; 69: 356–64PubMedCrossRefGoogle Scholar
  86. 86.
    Moussard C, Alber D, Toubin MM, et al. A drug used in traditional medicine, Harpagophytum procumbens: no evidence for NSAID-like effect on whole blood eicosanoid production in human. Prostaglandins Leukot Essent Fatty Acids 1992; 46: 283–6PubMedCrossRefGoogle Scholar
  87. 87.
    Borchers AT, Keen CL, Stern JS, et al. Inflammation and Native American medicine: the role of botanicals. Am J Clin Nutr 2000; 72: 339–47PubMedGoogle Scholar
  88. 88.
    Bauer R. Echinacea drugs: effects and active ingredients [in German]. Z Arztl Fortbild (Jena) 1996; 90: 111–5Google Scholar
  89. 89.
    Melchart D, Linde K, Fischer P, et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2000; (2): CD000530Google Scholar
  90. 90.
    Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine 2003; 10: 66–86PubMedCrossRefGoogle Scholar
  91. 91.
    Blumenthal M. The complete German commission E monographs, therapeutic guide to herbal medicines. Austin (TX): American Botanical Council, 1998Google Scholar
  92. 92.
    Osowski S, Rostock M, Bartsch HH, et al. Pharmaceutical comparability of different therapeutic Echinacea preperations [in German]. Forsch Komple-mentarmed Klass Naturheilkd 2000; 7: 294–300CrossRefGoogle Scholar
  93. 93.
    Perry NB, Burgess EJ, Glennie VL. Echinacea standardization: analytical methods for phenolic compounds and typical levels in medicinal species. J Agric Food Chem 2001; 49: 1702–6PubMedCrossRefGoogle Scholar
  94. 94.
    Gilroy CM, Steiner JF, Byers T, et al. Echinacea and truth in labeling. Arch Intern Med 2003; 163: 699–704PubMedCrossRefGoogle Scholar
  95. 95.
    Mullins RJ, Heddle R. Adverse reactions associated with echinacea: the Australian experience. Ann Allergy Asthma Immunol 2002; 88: 42–51PubMedCrossRefGoogle Scholar
  96. 96.
    Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7: 273–82PubMedCrossRefGoogle Scholar
  97. 97.
    Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004; 11: 98–104PubMedCrossRefGoogle Scholar
  98. 98.
    Dresser GK, McDonald W, Kim RB, et al. Evaluation of herbal products as potential inhibitors of MDR1 [abstract]. Clin Pharmacol Ther 2004; 75: P79CrossRefGoogle Scholar
  99. 99.
    Manku MS, Horrobin DF, Morse NL, et al. Essential fatty acids in the plasma phospholipids of patients with atopic eczema. Br J Dermatol 1984; 110: 643–8PubMedCrossRefGoogle Scholar
  100. 100.
    Horrobin DF, Manku MS. Premenstrual syndrome and premenstrual breast pain (cyclical mastalgia): disorders of essential fatty acid (EFA) metabolism. Prostaglandins Leukot Essent Fatty Acids 1989; 37: 255–61PubMedCrossRefGoogle Scholar
  101. 101.
    Morse PF, Horrobin DF, Manku MS, et al. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema: relationship between plasma essential fatty acid changes and clinical response. Br J Dermatol 1989; 121: 75–90PubMedCrossRefGoogle Scholar
  102. 102.
    Little C, Parsons T. Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev 2001; (1): CD002948Google Scholar
  103. 103.
    Hardy ML. Herbs of special interest to women. J Am Pharm Assoc (Wash) 2000; 40: 234–42Google Scholar
  104. 104.
    Martens-Lobenhoffer J, Meyer FP. Pharmacokinetic data of gamma-linolenic acid in healthy volunteers after the administration of evening primrose oil (Epogam). Int J Clin Pharmacol Ther 1998; 36: 363–6PubMedGoogle Scholar
  105. 105.
    Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2003; (2): CD001257Google Scholar
  106. 106.
    Lawson LD, Wang ZJ, Hughes BG. Identification and HPLC quantitation of the sulfides and dialk(en)yl thiosulfinates in commercial garlic products. Planta Med 1991; 57: 363–70PubMedCrossRefGoogle Scholar
  107. 107.
    Amagase H, Petesch BL, Matsuura H, et al. Intake of garlic and its bioactive components. J Nutr 2001; 131: 955S–62SPubMedGoogle Scholar
  108. 108.
    Lawson LD, Wang ZJ. Low allicin release from garlic supplements: a major problem due to the sensitivities of alliinase activity. J Agric Food Chem 2001; 49: 2592–9PubMedCrossRefGoogle Scholar
  109. 109.
    Schulz V, Hänsel R, Tyler VE. Rational phytotherapy: a physicians’ guide to herbal medicine. 4th ed. Berlin: Springer Verlag, 2001Google Scholar
  110. 110.
    Ackermann RT, Mulrow CD, Ramirez G, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 2001; 161: 813–24PubMedCrossRefGoogle Scholar
  111. 111.
    Kiesewetter H, Jung F, Pindur G, et al. Effect of garlic on thrombocyte aggregation, microcirculation, and other risk factors. Int J Clin Pharmacol Ther Toxicol 1991; 29: 151–5PubMedGoogle Scholar
  112. 112.
    Li G, Shi Z, Jia H, et al. A clinical investigation on garlicin injectio for treatment of unstable angina pectoris and its actions on plasma endothelin and blood sugar levels. J Tradit Chin Med 2000; 20: 243–6PubMedGoogle Scholar
  113. 113.
    Jain AK, Vargas R, Gotzkowsky S, et al. Can garlic reduce levels of serum lipids? A controlled clinical study. Am J Med 1993; 94: 632–5PubMedCrossRefGoogle Scholar
  114. 114.
    Bordia A, Verma SK, Srivastava KC. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 257–63PubMedCrossRefGoogle Scholar
  115. 115.
    Sitprija S, Plengvidhya C, Kangkaya V, et al. Garlic and diabetes mellitus phase II clinical trial. J Med Assoc Thai 1987; 70Suppl. 2: 223–7PubMedGoogle Scholar
  116. 116.
    Mansell P, Reckless JP, Lloyd J. The effect of dried garlic powder tablets on serum lipids in non-insulin dependent diabetic patients. Eur J Clin Res 1996; 8: 25–6Google Scholar
  117. 117.
    Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol 2002; 81: 81–100PubMedCrossRefGoogle Scholar
  118. 118.
    Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003; 60: 356–9PubMedGoogle Scholar
  119. 119.
    Ali M, Thomson M, Afzal M. Garlic and onions: their effect on eicosanoid metabolism and its clinical relevance. Prostaglandins Leukot Essent Fatty Acids 2000; 62: 55–73PubMedCrossRefGoogle Scholar
  120. 120.
    Rahman K, Billington D. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. J Nutr 2000; 130: 2662–5PubMedGoogle Scholar
  121. 121.
    Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacol 1998; 31: 904–8PubMedCrossRefGoogle Scholar
  122. 122.
    Bordia A, Verma SK, Srivastava KC. Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 201–5PubMedCrossRefGoogle Scholar
  123. 123.
    Kiesewetter H, Jung F, Jung EM, et al. Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack. Eur J Clin Pharmacol 1993; 45: 333–6PubMedCrossRefGoogle Scholar
  124. 124.
    Legnani C, Frascaro M, Guazzaloca G, et al. Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. Arzneimittelforschung 1993; 43: 119–22PubMedGoogle Scholar
  125. 125.
    Jain RC. Effect of garlic on serum lipids, coagulability and fibrinolytic activity of blood. Am J Clin Nutr 1977; 30: 1380–1PubMedGoogle Scholar
  126. 126.
    Rose KD, Croissant PD, Parliament CF, et al. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery 1990; 26: 880–2PubMedCrossRefGoogle Scholar
  127. 127.
    German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. Br J Urol 1995; 76: 518PubMedCrossRefGoogle Scholar
  128. 128.
    Burnham BE. Garlic as a possible risk for postoperative bleeding. Plast Reconstr Surg 1995; 95: 213PubMedGoogle Scholar
  129. 129.
    Harenberg J, Giese C, Zimmermann R. Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia. Atherosclerosis 1988; 74: 247–9PubMedCrossRefGoogle Scholar
  130. 130.
    Luley C, Lehmann-Leo W, Moller B, et al. Lack of efficacy of dried garlic in patients with hyperlipoproteinemia. Arzneimittelforschung 1986; 36: 766–8PubMedGoogle Scholar
  131. 131.
    Siess MH, Le Bon AM, Canivenc-Lavier MC, et al. Modification of hepatic drug-metabolizing enzymes in rats treated with alkyl sulfides. Cancer Lett 1997; 120: 195–201PubMedCrossRefGoogle Scholar
  132. 132.
    Sheen LY, Chen HW, Kung YL, et al. Effects of garlic oil and its organosulfur compounds on the activities of hepatic drug-metabolizing and antioxidant enzymes in rats fed high- and low-fat diets. Nutr Cancer 1999; 35: 160–6PubMedCrossRefGoogle Scholar
  133. 133.
    Guyonnet D, Siess MH, Le Bon AM, et al. Modulation of phase II enzymes by organosulfur compounds from allium vegetables in rat tissues. Toxicol Appl Pharmacol 1999; 154: 50–8PubMedCrossRefGoogle Scholar
  134. 134.
    Fujita K, Kamataki T. Screening of organosulfur compounds as inhibitors of human CYP2A6. Drug Metab Dispos 2001; 29: 983–9PubMedGoogle Scholar
  135. 135.
    Wu CC, Sheen LY, Chen HW, et al. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem 2002; 50: 378–83PubMedCrossRefGoogle Scholar
  136. 136.
    Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4: 176–84PubMedGoogle Scholar
  137. 137.
    Arora A, Seth K, Shukla Y. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis 2004; 25: 941–9PubMedCrossRefGoogle Scholar
  138. 138.
    Yang CS, Chhabra SK, Hong JY, et al. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J Nutr 2001; 131: 1041S–5SPubMedGoogle Scholar
  139. 139.
    DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 2000; 1: 25–58PubMedCrossRefGoogle Scholar
  140. 140.
    Blumenthal M. Herbs continue slide in mainstream market: sales down 14 percent. HerbalGram 2003; 58: 71Google Scholar
  141. 141.
    Birks J, Grimley EJ, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002; (4): CD003120Google Scholar
  142. 142.
    Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 2000; 108: 276–81PubMedCrossRefGoogle Scholar
  143. 143.
    Jaggy H, Koch E. Chemistry and biology of alkylphenols from Ginkgo biloba L. Pharmazie 1997; 52: 735–8PubMedGoogle Scholar
  144. 144.
    Kressmann S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002; 54: 661–9PubMedCrossRefGoogle Scholar
  145. 145.
    Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 2002; 67: 235–57PubMedCrossRefGoogle Scholar
  146. 146.
    Chung KF, Dent G, McCusker M, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987; I: 248–51CrossRefGoogle Scholar
  147. 147.
    Gilbert G J. Ginkgo biloba [letter]. Neurology 1997; 48: 1137PubMedCrossRefGoogle Scholar
  148. 148.
    Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998; 352: 36PubMedCrossRefGoogle Scholar
  149. 149.
    Benjamin J, Muir T, Briggs K, et al. A case of cerebral haemorrhage: can Ginkgo biloba be implicated? Postgrad Med J 2001; 77: 112–3PubMedCrossRefGoogle Scholar
  150. 150.
    Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 2001; 67: 33–5PubMedGoogle Scholar
  151. 151.
    Schneider C, Bord C, Misse P, et al. Spontaneous hyphema caused by Ginkgo biloba extract [in French]. J Fr Ophtalmol 2002; 25: 731–2PubMedGoogle Scholar
  152. 152.
    Fong KC, Kinnear PE. Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion. Postgrad Med J 2003; 79: 531–2PubMedCrossRefGoogle Scholar
  153. 153.
    Israeli A, Matzner Y, Or R, et al. Glibenclamide causing thrombocytopenia and bleeding tendency: case reports and a review of the literature. Klin Wochenschr 1988; 66: 223–4PubMedCrossRefGoogle Scholar
  154. 154.
    Weaver AL. Rofecoxib: clinical pharmacology and clinical experience. Clin Ther 2001; 23: 1323–38PubMedCrossRefGoogle Scholar
  155. 155.
    Kim YS, Pyo MK, Park KM, et al. Antiplatelet and antithrombotic effects of a combination of ticlopidine and Ginkgo biloba ext (EGb 761). Thromb Res 1998; 91: 33–8PubMedCrossRefGoogle Scholar
  156. 156.
    Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine 2005; 12: 10–6PubMedCrossRefGoogle Scholar
  157. 157.
    Guinot P, Caffrey E, Lambe R, et al. Tanakan inhibits platelet-activating-factorinduced platelet aggregation in healthy male volunteers. Haemostasis 1989; 19: 219–23PubMedGoogle Scholar
  158. 158.
    Jung F, Mrowietz C, Kiesewetter H, et al. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 1990; 40: 589–93PubMedGoogle Scholar
  159. 159.
    Bal Dit Sollier C, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol 2003; 25: 251–3PubMedCrossRefGoogle Scholar
  160. 160.
    Mehlsen J, Drabaek H, Wiinberg N, et al. Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers. Clin Physiol Funct Imaging 2002; 22: 375–8PubMedCrossRefGoogle Scholar
  161. 161.
    Nilsson OG, Lindgren A, Stahl N, et al. Incidence of intracerebral and subarachnoid haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatry 2000; 69: 601–7PubMedCrossRefGoogle Scholar
  162. 162.
    Jezova D, Duncko R, Lassanova M, et al. Reduction of rise in blood pressure and Cortisol release during stress by Ginkgo biloba extract (EGb 761) in healthy volunteers. J Physiol Pharmacol 2002; 53: 337–48PubMedGoogle Scholar
  163. 163.
    Lagrue G, Behar A, Kazandjian M, et al. Idiopathic cyclic edema: the role of capillary hyperpermeability and its correction by Ginkgo biloba extract [in French]. Presse Med 1986; 15: 1550–3PubMedGoogle Scholar
  164. 164.
    Sasaki K, Hatta S, Haga M, et al. Effects of bilobalide on gamma-aminobutyric acid levels and glutamic acid decarboxylase in mouse brain. Eur J Pharmacol 1999; 367: 165–73PubMedCrossRefGoogle Scholar
  165. 165.
    Schubert H, Halama P. Primär therapieresistente depressive Verstimmung älterer Patienten mit Hirnleistungsstörrungen: Wirksamkeit der Kombination von Ginkgo-biloba-Extrakt EGb 761 mit Antidepressiva. Geriat Forsch 1993; 3: 45–53Google Scholar
  166. 166.
    Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998; 24: 139–43PubMedCrossRefGoogle Scholar
  167. 167.
    Wheatley D. Ginkgo biloba relieves sexual dysfunction due to antidepressant drags. Eur Neuropsychopharmacol 1999; 9: S253–4CrossRefGoogle Scholar
  168. 168.
    Ashton AK, Ahrens K, Gupta S, et al. Antidepressant-induced sexual dysfunction and Ginkgo biloba. Am J Psychiatry 2000; 157: 836–7PubMedCrossRefGoogle Scholar
  169. 169.
    Kang BJ, Lee SJ, Kim MD, et al. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol 2002; 17: 279–84PubMedCrossRefGoogle Scholar
  170. 170.
    Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2001; 62: 878–83PubMedCrossRefGoogle Scholar
  171. 171.
    Gregory PJ. Scizure associated with Ginkgo bilobal [letter]. Ann Intern Med 2001; 134: 344PubMedGoogle Scholar
  172. 172.
    Kajiyama Y, Fujii K, Takeuchi H, et al. Ginkgo seed poisoning. Pediatrics 2002; 109: 325–7PubMedCrossRefGoogle Scholar
  173. 173.
    Miwa H, Iijima M, Tanaka S, et al. Generalized convulsions after consuming a large amount of gingko nuts. Epilepsia 2001; 42: 280–1PubMedGoogle Scholar
  174. 174.
    Arenz A, Klein M, Fiehe K, et al. Occurrence of neurotoxic 4′-0-methylpyridoxin in Ginkgo biloba leaves, medications and Japanese ginkgo food. Planta Med 1996; 62: 548–51PubMedCrossRefGoogle Scholar
  175. 175.
    Wada K, Ishigaki S, Ueda K, et al. An antivitamin B6, 4′-methoxypyridoxine, from the seed of Ginkgo biloba L. Chem Pharm Bull (Tokyo) 1985; 33: 3555–7CrossRefGoogle Scholar
  176. 176.
    Manocha A, Pillai KK, Husain SZ. Effect of Ginkgo biloba on chemoshock in mice. Ind J Pharmacol 1997; 29: 198–200Google Scholar
  177. 177.
    Manocha A, Pillai KK, Husain SZ. Influence of Ginkgo biloba on the effect of anticonvulsants. Indian J Pharmacol 1996; 28: 84–7Google Scholar
  178. 178.
    Gaudineau C, Beckerman R, Welboum S, et al. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun 2004; 318: 1072–8PubMedCrossRefGoogle Scholar
  179. 179.
    von Moltke LL, Weemhoff JL, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004; 56: 1039–44CrossRefGoogle Scholar
  180. 180.
    Mahady GB, Chadwick LR. Goldenseal (Hydrastis canadensis): is there enough scientific evidence to support safety and efficacy? Nutr Clin Care 2001; 4: 243–9CrossRefGoogle Scholar
  181. 181.
    Edwards DJ, Draper EJ. Variations in alkaloid content of herbal products containing goldenseal. J Am Pharm Assoc 2003; 43: 419–23CrossRefGoogle Scholar
  182. 182.
    Foster BC, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003; 10: 334–42PubMedCrossRefGoogle Scholar
  183. 183.
    Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drag Metab Dispos 2003; 31: 1391–7CrossRefGoogle Scholar
  184. 184.
    Lin HL, Liu TY, Lui WY, et al. Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. Cancer 1999; 85: 1937–42PubMedGoogle Scholar
  185. 185.
    Maeng HJ, Yoo HJ, Kim IW, et al. P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci 2002; 91: 2614–21PubMedCrossRefGoogle Scholar
  186. 186.
    Rigelsky JM, Sweet BV. Hawthorn: pharmacology and therapeutic uses. Am J Health Syst Pharm 2002; 59: 417–22PubMedGoogle Scholar
  187. 187.
    Vierling W, Brand N, Gaedcke F, et al. Investigation of the pharmaceutical and pharmacological equivalence of different hawthorn extracts. Phytomedicine 2003; 10: 8–16PubMedCrossRefGoogle Scholar
  188. 188.
    Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003; 114: 665–74PubMedCrossRefGoogle Scholar
  189. 189.
    Weikl A, Assmus KD, Neukum-Schmidt A, et al. Crataegus special extract WS 1442: assessment of objective effectiveness in patients with heart failure (NYHA II) [in German]. Fortschr Med 1996; 114: 291–6PubMedGoogle Scholar
  190. 190.
    Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002; 143: 910–5PubMedCrossRefGoogle Scholar
  191. 191.
    Wolkerstorfer H. Treatment of heart disease with a digoxin-crataegus combination [in German]. Munch Med Wochenschr 1966; 108: 438–41PubMedGoogle Scholar
  192. 192.
    Holubarsch CJ, Colucci WS, Meinertz T, et al. Survival and Prognosis: Investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE): rationale, study design and study protocol. Eur J Heart Fail 2000; 2: 431–7PubMedCrossRefGoogle Scholar
  193. 193.
    Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003; (1): CD003383Google Scholar
  194. 194.
    Mathews JD, Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 1988; 148: 548–55PubMedGoogle Scholar
  195. 195.
    From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products: United States, Germany, and Switzerland, 1999–2002. JAMA 2003; 289: 36–7CrossRefGoogle Scholar
  196. 196.
    Bauer R, Kopp B, Nahrstedt A. Relevant hepatotoxic effects of kava still need to be proven: a statement of the society for medicinal plant research. Planta Med 2003; 69: 971–2CrossRefGoogle Scholar
  197. 197.
    Anke J, Ramzan I. Kava hepatotoxicity: are we any closer to the truth. Planta Med 2004; 70: 193–6PubMedCrossRefGoogle Scholar
  198. 198.
    Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68–9PubMedGoogle Scholar
  199. 199.
    Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett 2004; 150: 85–96PubMedCrossRefGoogle Scholar
  200. 200.
    Zou L, Harkey MR, Henderson GL, et al. Kava does not display metabolic toxicity in a homogeneous cellular assay. Planta Med 2004; 70: 289–92PubMedCrossRefGoogle Scholar
  201. 201.
    Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drag Metab Dispos 2002; 30: 1153–7CrossRefGoogle Scholar
  202. 202.
    Unger M, Holzgrabe U, Jacobsen W, et al. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med 2002; 68: 1055–8PubMedCrossRefGoogle Scholar
  203. 203.
    Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by Pharmaceuticals and natural products. Drug Metab Dispos 2003; 31: 533–9PubMedCrossRefGoogle Scholar
  204. 204.
    Zou L, Henderson GL, Harkey MR, et al. Effects of kava (kava-kava, ‘Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 2004; 11: 285–94PubMedCrossRefGoogle Scholar
  205. 205.
    Cote CS, Kor C, Cohen J, et al. Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Commun 2004; 322: 147–52PubMedCrossRefGoogle Scholar
  206. 206.
    Spillane PK, Fisher DA, Currie BJ. Neurological manifestations of kava intoxication. Med J Aust 1997; 167: 172–3PubMedGoogle Scholar
  207. 207.
    Dinh LD, Simmen U, Bueter KB, et al. Interaction of various Piper methysticum cultivars with CNS receptors in vitro. Planta Med 2001; 67: 306–11PubMedCrossRefGoogle Scholar
  208. 208.
    Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 1105–20PubMedCrossRefGoogle Scholar
  209. 209.
    Boerner RJ, Klement S. Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490. Wien Med Wochenschr 2004; 154: 508–10PubMedCrossRefGoogle Scholar
  210. 210.
    Friese J, Gleitz J. Kavain, dihydrokavain, and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated Na+ channels. Planta Med 1998; 64: 458–9PubMedCrossRefGoogle Scholar
  211. 211.
    Gleitz J, Friese J, Beile A, et al. Anticonvulsive action of (+/−)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol 1996; 315: 89–97PubMedCrossRefGoogle Scholar
  212. 212.
    Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994; 116: 469–74CrossRefGoogle Scholar
  213. 213.
    Woelk H, Kapoula O, Lehrl S, et al. Treatment of anxiety patients. Double-blind study: kava special extract WS 1490 versus benzodiazepine [in German]. Z Allg Med 1993; 69: 271–7Google Scholar
  214. 214.
    Geßner B, Cnota P. Untersuchungen der Vigilanz nach Applikation von Kava-Kava-Extrakt, Diazepam oder Plazebo. Z Phytother 1994; 15: 30–7Google Scholar
  215. 215.
    Davis KM, Wu JY. Role of glutamatergic and GABAergic systems in alcoholism. J Biomed Sci 2001; 8: 7–19PubMedCrossRefGoogle Scholar
  216. 216.
    Rotblatt MD. Cranberry, feverfew, horse chestnut, and kava. West J Med 1999; 171: 195–8PubMedGoogle Scholar
  217. 217.
    Perez J, Holmes JF. Altered mental status and ataxia secondary to acute Kava ingestion. J Emerg Med 2005; 28: 49–51PubMedCrossRefGoogle Scholar
  218. 218.
    Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol 1990; 17: 509–14PubMedCrossRefGoogle Scholar
  219. 219.
    Sailer R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drags 2001; 61: 2035–63CrossRefGoogle Scholar
  220. 220.
    Wagner H, Diesel P, Scitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn [in German]. Arzneimittelforschung 1974; 24: 466–71PubMedGoogle Scholar
  221. 221.
    Enjalbert F, Rapior S, Nouguier-Soule J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002; 40: 715–57PubMedCrossRefGoogle Scholar
  222. 222.
    Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86: 250–6PubMedCrossRefGoogle Scholar
  223. 223.
    Venkataramanan R, Ramachandran V, Komoroski BJ, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000; 28: 1270–3PubMedGoogle Scholar
  224. 224.
    Zuber R, Modriansky M, Dvorak Z, et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 2002; 16: 632–8PubMedCrossRefGoogle Scholar
  225. 225.
    Zhang S, Morris ME. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 2003; 20: 1184–91PubMedCrossRefGoogle Scholar
  226. 226.
    Jordt SE, McKemy DD, Julius D. Lessons from peppers and peppermint: the molecular logic of thermosensation. Curr Opin Neurobiol 2003; 13: 487–92PubMedCrossRefGoogle Scholar
  227. 227.
    Hawthorn M, Ferrante J, Luchowski E, et al. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther 1988; 2: 101–18PubMedCrossRefGoogle Scholar
  228. 228.
    Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle: an analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991; 101: 55–65PubMedGoogle Scholar
  229. 229.
    Eccles R. Menthol: effects on nasal sensation of airflow and the drive to breathe. Curr Allergy Asthma Rep 2003; 3: 210–4PubMedCrossRefGoogle Scholar
  230. 230.
    Gobel H, Fresenius J, Heinze A, et al. Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German]. Nervenarzt 1996; 67: 672–81PubMedCrossRefGoogle Scholar
  231. 231.
    Javorka K, Tomori Z, Zavarska L. Protective and defensive airway reflexes in premature infants. Physiol Bohemoslov 1980; 29: 29–35PubMedGoogle Scholar
  232. 232.
    Wyllie JP, Alexander FW. Nasal instillation of ‘Olbas Oil’ in an infant. Arch Dis Child 1994; 70: 357–8PubMedCrossRefGoogle Scholar
  233. 233.
    Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998; 93: 1131–5PubMedCrossRefGoogle Scholar
  234. 234.
    Dalvi SS, Nadkarni PM, Pardesi R, et al. Effect of peppermint oil on gastric emptying in man: a preliminary study using a radiolabelled solid test meal. Indian J Physiol Pharmacol 1991; 35: 212–4PubMedGoogle Scholar
  235. 235.
    Micklefield GH, Greving I, May B. Effects of peppermint oil and caraway oil on gastroduodenal motility. Phytother Res 2000; 14: 20–3PubMedCrossRefGoogle Scholar
  236. 236.
    Goerg KJ, Spilker T. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time. Aliment Pharmacol Ther 2003; 17: 445–51PubMedCrossRefGoogle Scholar
  237. 237.
    Gelal A, Guven H, Balkan D, et al. Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers. Eur J Clin Pharmacol 2003; 59: 417–22PubMedCrossRefGoogle Scholar
  238. 238.
    Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 2001; 53: 1323–9PubMedCrossRefGoogle Scholar
  239. 239.
    Wacher VJ, Wong S, Wong HT. Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. J Pharm Sci 2002; 91: 77–90PubMedCrossRefGoogle Scholar
  240. 240.
    Wilt T, Ishani A, MacDonald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002; (3): CD001423Google Scholar
  241. 241.
    Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004; 7: 195–200PubMedCrossRefGoogle Scholar
  242. 242.
    Buck AC. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 2004; 172: 1792–9PubMedCrossRefGoogle Scholar
  243. 243.
    Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of saw palmetto herb: a case report and review of literature. J Intern Med 2001; 250: 167–9PubMedCrossRefGoogle Scholar
  244. 244.
    Houghton PJ. The scientific basis for the reputed activity of valerian. J Pharm Pharmacol 1999; 51: 505–12PubMedCrossRefGoogle Scholar
  245. 245.
    Bounthanh C, Bergmann C, Beck JP, et al. Valepotriates, a new class of cytotoxic and antitumor agents. Planta Med 1981; 41: 21–8PubMedCrossRefGoogle Scholar
  246. 246.
    Bos R, Hendriks H, Scheffer JJC, et al. Cytotoxic potential of valerian constituents and valerian tinctures. Phytomedicine 1998; 5: 219–25PubMedCrossRefGoogle Scholar
  247. 247.
    Shohet D, Wills RBH, Stuart DL. Valepotriates and valerenic acids in commercial preparations of valerian available in Australia. Pharmazie 2001; 56: 860–3PubMedGoogle Scholar
  248. 248.
    MacGregor FB, Abernethy VE, Dahabra S, et al. Hepatotoxicity of herbal remedies. BMJ 1989; 299: 1156–7PubMedCrossRefGoogle Scholar
  249. 249.
    Chan TY, Tang CH, Critchley JA. Poisoning due to an over-the-counter hypnotic, Sleep-Qik (hyoscine, cyproheptadine, valerian). Postgrad Med J 1995; 71: 227–8PubMedCrossRefGoogle Scholar
  250. 250.
    Chan TY. An assessment of the delayed effects associated with valerian overdose. Int J Clin Pharmacol Ther 1998; 36: 569PubMedGoogle Scholar
  251. 251.
    Riedel E, Hansel R, Ehrke G. Inhibition of gamma-aminobutyric acid catabolism by valerenic acid derivatives [in German]. Planta Med 1982; 46: 219–20PubMedCrossRefGoogle Scholar
  252. 252.
    Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res 1999; 24: 1373–8PubMedCrossRefGoogle Scholar
  253. 253.
    Donath F, Quispe S, Diefenbach K, et al. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000; 33: 47–53PubMedCrossRefGoogle Scholar
  254. 254.
    Dorn M. Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative study [in German]. Forsch Komplementarmed Klass Naturheilkd 2000; 7: 79–84PubMedCrossRefGoogle Scholar
  255. 255.
    Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998; 280: 1566–7PubMedCrossRefGoogle Scholar
  256. 256.
    Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000; 61: 5–10PubMedCrossRefGoogle Scholar
  257. 257.
    van der Mast RC, Fekkes D. Serotonin and amino acids: partners in delirium pathophysiology? Semin Clin Neuropsychiatry 2000; 5: 125–31PubMedGoogle Scholar
  258. 258.
    Schwartz RH, Rodriquez WJ. Toxic delirium possibly caused by loperamide. J Pediatr 1991; 118: 656–7PubMedGoogle Scholar
  259. 259.
    Chang PH, Steinberg MB. Alcohol withdrawal. Med Clin North Am 2001; 85: 1191–212PubMedCrossRefGoogle Scholar
  260. 260.
    Leuschner J, Muller J, Rudmann M. Characterisation of the central nervous depressant activity of a commercially available valerian root extract. Arzneimittelforschung 1993; 43: 638–41PubMedGoogle Scholar
  261. 261.
    Waked M, Bismuth C, Capron F, et al. Lipid pneumonia discovered in a case of epiphenomenal drug poisoning [in French]. Presse Med 1991; 20: 178PubMedGoogle Scholar
  262. 262.
    Willey LB, Mady SP, Cobaugh DJ, et al. Valerian overdose: a case report. Vet Hum Toxicol 1995; 37: 364–5PubMedGoogle Scholar
  263. 263.
    Wells SR. Intentional intravenous administration of a crude valerian root extract [abstract]. J Toxicol Clin Toxicol 1995; 33: 542Google Scholar
  264. 264.
    Mullins ME, Horowitz BZ. The case of the salad shooters: intravenous injection of wild lettuce extract. Vet Hum Toxicol 1998; 40: 290–1PubMedGoogle Scholar
  265. 265.
    Barnes J, Mills SY, Abbot NC, et al. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496–500PubMedCrossRefGoogle Scholar
  266. 266.
    Ernst E. Challenges for phytopharmacovigilance. Postgrad Med J 2004; 80: 249–50PubMedCrossRefGoogle Scholar
  267. 267.
    Butterweck V, Derendorf H, Gaus W, et al. Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate? Planta Med 2004; 70: 784–91PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Institut für Klinische Pharmakologie, Charité, Campus MitteUniversitätsmedizin CharitéBerlinGermany

Personalised recommendations